Evidence map›Paper›PMID 22879984›Full record

ArticlePloS one2012

Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera.

Gregory A Price, Randall K Holmes

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Outer membrane vesicles inMicrobial cell (Graz, Austria) · 2026
    Article
  2. Dynamics of IgM and IgA Antibody Response Profile AgainstInternational journal of molecular sciences · 2025
    Article
  3. Article
  4. Frontiers in medicine · 2023
    Review
  5. B-Cell Epitope Mapping of theInternational journal of molecular sciences · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gregory A PriceDepartment of Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
Randall K Holmes
University of Colorado Denver · US

Funding

GENETIC ANALYSIS OF CHOLERA TOXIN STRUCTURE AND FUNCTIONR01AI031940 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLMES, RANDALL K · 1992 to 2011
$5.9M
NIAID NIH HHS R01 AI031940NIAID NIH HHS R01-AI31940
6 · The paper itself

Abstract

The secreted colonization factor, TcpF, which is produced by Vibrio cholerae 01 and 0139, has generated interest as a potential protective antigen in the development of a subunit vaccine against cholera. This study evaluated immunogenicity/protective efficacy of a TcpF holotoxin-like chimera (TcpF-A2-CTB) following intraperitoneal immunization compared to TcpF alone, a TcpF+CTB mixture, or CTB alone. Immunization with the TcpF-A2-CTB chimera elicited significantly greater amounts of anti-TcpF IgG than immunization with the other antigens (P<0.05). Protective efficacy was measured using 6-day-old pups reared from immunized dams and orogastrically challenged with a lethal dose of El Tor V. cholerae 01 Inaba strain N16961. Protection from death, and weight loss analysis at 24 and 48 hours post-infection demonstrated that immunization with TcpF alone was poorly protective. However, immunization with TcpF+CTB was highly protective and showed a trend toward greater protection than immunization with CTB alone (82% vs 64% survival). Immunization with the TcpF-A2-CTB chimera demonstrated less protection (50% survival) than immunization with the TcpF+CTB mixture. The TcpF-A2-CTB chimera used for this study contained the heterologous classical CTB variant whereas the El Tor CTB variant (expressed by the challenge strain) was used in the other immunization groups. For all immunization groups that received CTB, quantitative ELISA data demonstrated that the amounts of serum IgG directed against the homologous immunizing CTB antigen was statistically greater than the amount to the heterologous CTB antigen (P≤0.003). This finding provides a likely explanation for the poorer protection observed following immunization with the TcpF-A2-CTB chimera and the relatively high level of protection seen after immunization with homologous CTB alone. Though immunization with TcpF alone provided no protection, the additive protective effect when TcpF was combined with CTB demonstrates its possible value as a component of a multivalent subunit vaccine against Vibrio cholerae 01 and 0139.

Indexed as

ImmunizationAnimalsAnimals, NewbornAnimals, SucklingAntibodies, BacterialAntibody FormationAntibody SpecificityBacterial ProteinsCholeraCholera ToxinDisease Models, AnimalElectrophoresis, Polyacrylamide GelEnzyme-Linked Immunosorbent AssayFecesGenotypeImmunoglobulin AAntibodies, BacterialBacterial ProteinsCholera ToxinImmunoglobulin ARecombinant Fusion ProteinstcpN protein, Vibrio choleraeTranscription Factors

Identifiers

PMID22879984
PMCPMC3413659
OpenAlexW2043242440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.